The US Food and Drug Administration (FDA) has granted Accuray Inc, Sunnyvale, Calif, 510(k) clearance to market its Lung Optimized Treatment, a new component of the company’s CyberKnife® VSI™ System. The CyberKnife System is for use in radiosurgery treatments to patients with lung cancer.
According to the company, because fiducial implantation is no longer required, CyberKnife radiosurgery with Lung Optimized Treatment offers a completely non-invasive option, which is particularly important for medically and surgically inoperable patients. This means patients who are not candidates for fiducial placement or physicians who choose not to implant fiducials due to high risk of pneumothorax, now have a noninvasive alternative using the CyberKnife System’s unique tracking and correction capabilities.
Source: Accuray Inc
